Navigation Links
Dr. H. Daniel Perez Joins Celtaxsys Board of Directors
Date:6/6/2011

SAN FRANCISCO, June 6, 2011 /PRNewswire/ -- Celtaxsys, Inc., a private biopharmaceutical company defining new therapeutics in inflammation, announces the appointment of life sciences industry veteran, H. Daniel Perez, M.D., to its Board of Directors (BOD).

"We are delighted that Dr. Perez has joined the Celtaxsys team," says Dr. Michael R. Hanley, CEO and Chairman of the Board of Celtaxsys. "He brings more than 25 years of high level pharmaceutical executive experience to the BOD, in addition to scientific and commercial accomplishments related to Celtaxsys' mission.  We look forward to working closely with Dr. Perez."  

"I am excited about the opportunities that an innate immunity company brings to the therapeutic field," commented Dr. Perez. "This is an area that is close to my heart and has not received the attention that it deserves.  I believe Celtaxsys will bring new paradigms to the forefront of innovative therapeutics."

H. Daniel Perez, M.D., is a Venture Partner with Bay City Capital, and was previously President and CEO of Berlex Biosciences until its acquisition by Bayer in 2006. He is on the Board of Directors of Cleveland Biolabs (a public company, CBLI), Presidio Pharmaceuticals, and F&P Pharmaceuticals (privately held companies), the Scientific Advisory Boards of Cardium (a public company, CDTP, CXM), Vertex Pharmaceuticals neurodegenerative diseases (VRTX, Nasdaq), Glaxo GSK, (Neuroinflammation, China) and the Advisory Board for the Gladstone Institutes at the University of California, San Francisco (UCSF). Dr. Perez received his medical degree in Buenos Aires, Argentina and completed his medical training at Beth Israel-Mount Sinai and New York University, in New York City. Dr. Perez has published extensively and is the author of a number of patents.

About Celtaxsys

Celtaxsys is a privately-held early discovery company with operations in San Francisco, CA and Atlanta, GA. The Company is focused on the discovery and development of therapeutics to treat inflammation by control of innate immunity. Celtaxsys has pioneered an innovative technology platform to identify novel immunoregulators based on migration and activation of cells from the innate immune system. Lead candidates are undergoing preclinical optimization.


'/>"/>
SOURCE Celtaxsys, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
2. Datafarm, Inc., Announces the Appointment of Daniel F. Orfe to Vice President, Global Regulatory Submission Services
3. Dr. Daniel Ronel Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler
4. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
5. BMP Sunstone Appoints Daniel Harrington to Board of Directors
6. Daniel Dunn Joins Brooks Instrument as Director of Customer Service
7. Rensselaer professor Daniel Lewis receives NSF CAREER Award
8. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
9. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
Breaking Biology News(10 mins):